Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Anexon, Incorporated | INDUSTRY |
| Celerion | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The purpose of this study was to investigate the safety and tolerability of ANX-042 when administered by continuous intravenous (IV) infusion in healthy volunteers.
Each participant received a total of two, approximately 12-hour continuous infusions of ANX-042 and one 12-hour continuous infusion of placebo, with a 36-hour washout period between treatments.
This study was conducted by Anexon, Inc. at Celerion, in Lincoln, Nebraska.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ANX-042: 0.001 mcg/kg/min (with low sodium diet) | Experimental | 0.001 dose unit equal to 1 millionth of a gram of an ANX-042 preparation / 1 kilogram of body mass administered / unit of time equal to 1 minute(mcg/kg/min), w/ diet restricted to 2.5 grams (gm) per day sodium (Na+) and 2.1 liters (L) fluid total daily intake |
|
| ANX-042: 0.001 mcg/kg/min | Experimental | 0.001 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake |
|
| ANX-042: 0.003 mcg/kg/min (low sodium diet) | Experimental | 0.003 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake |
|
| ANX-042: 0.003 mcg/kg/min | Experimental | 0.003 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake |
|
| ANX-042: 0.0065 mcg/kg/min (low sodium diet) | Experimental | 0.0065 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ANX-042 | Drug | Reconstituted in Sterile Water for Injection, United States Pharmacopeia (USP) and administered by 12 hour continuous intravenous infusion with 5% dextrose in water (D5W), United States Pharmacopeia (USP) |
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants with one or more drug-related adverse events (AEs) or any serious AEs | 0 to 4 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Pharmacokinetics: Area under the plasma concentration-time curve (AUC) of ANX-042 | 0 to 24 hours post dose | |
| Pharmacokinetics: Steady state plasma concentration of ANX-042 | 12 hours post dose |
Not provided
Inclusion Criteria:
Men or women of non-reproductive potential (WNRP)
Good health status, physically active without cardio-respiratory limitations and minimal concomitant medications as determined by medical history and physical examination
Able and willing to comply with study procedures, including controlled sodium (Na) intake and restriction of caffeine and tobacco product
Have given written informed consent prior to the initiation of any study procedures
Exclusion Criteria:
History of cardiovascular disease, unexplained syncope, postural tachycardia syndrome or frequent postural hypotension
History or current evidence of respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders that would constitute a risk when taking the study medication or interfere with the interpretation of data
Clinically significantly abnormal clinical laboratory results (including Hepatitis B, Hepatitis C and Human Immunodeficiency Virus (HIV) serology) or physical examination results (confirmed by repeat measurement, if appropriate) that, in the opinion of the Investigator, would constitute a risk when taking the study medication or interfere with the interpretation of data
Abnormal orthostatic Blood Pressure/Heart Rate (BP/HR) response at screening as defined by:
One or two supine values must be obtained between 8 and 10 minutes of supine rest. One or two upright values must be obtained between 3 and 5 minutes upright with the arm passively supported to maintain the brachial artery at heart level
Abnormal 12-lead electrocardiogram (ECG) that interferes with proper measurement of QT-interval or, in the opinion of the Investigator, increases the risk of participating in the study
Elevated BP (>140/90 mmHg) in any posture, confirmed by repeat measurement
Current use (within 7 days of first dosing) or expected need for concomitant medications with hemodynamic effects including: non-steroidal anti-inflammatory drugs (NSAIDS), decongestants, BP medications, diuretics, monoamine oxidase inhibitors, norepinephrine uptake inhibitors (for example, attention-deficit disorder medications, anti-depressants) and erectile dysfunction medications. Medications with low likelihood of hemodynamic or renal effects are permitted (for example, acetaminophen, vitamins, stable thyroid hormone, gastritis therapies, antihistamines, topical medications, et cetera) after approval by the Investigator
Evidence of current or recent use of known drugs of abuse and/or positive findings on urinary drug screening
History of an average weekly alcohol intake that exceeds 21 units per week (1 unit equal to (=) 12 ounces (oz) or 360 milliliters (mL) of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits), or are unwilling to stop alcohol consumption for the duration of the study
History of regular smoking of >5 cigarettes, cigars and/or pipe bowls of tobacco per day
Known allergies to nesiritide (Natrecor)
History of blood donation of >500 mL within one month, or plasma donation within 14 days, of first dosing
Are currently enrolled in, or have completed or discontinued within the last 30 days from, a clinical trial involving an investigational product or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
Are investigator site personnel directly affiliated with this study or their immediate family members. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted
Are Lilly or Anexon employees or employees of any third-party organization (TPO) involved with the study that require exclusion of their employees
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Email: Anexon@Choruspharma.com | Anexon, Incorporated | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Celerion | Lincoln | Nebraska | 68502 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ANX-042: 0.01 mcg/kg/min (low sodium diet) | Experimental | 0.01 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake |
|
| ANX-042: 0.01 mcg/kg/min | Experimental | 0.01 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake |
|
| ANX-042: 0.03 mcg/kg/min | Experimental | 0.03 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake |
|
| ANX-042: 0.1 mcg/kg/min | Experimental | 0.1 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake |
|
| ANX-042: 0.3 mcg/kg/min | Experimental | 0.3 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake |
|
| Placebo (low sodium diet) | Placebo Comparator | Placebo and diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake |
|
| Placebo | Placebo Comparator | Placebo and diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake |
|
| Placebo | Drug | Administered once by 12 hour continuous intravenous infusion with D5W (USP) |
|